| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8541393 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(6 months from now) | |
| US9339036 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
Nov, 2024
(6 months from now) | |
| US7696182 | CORMEDIX | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
May, 2025
(1 year, 18 days from now) | |
| US11738120 | CORMEDIX | Synthesis of taurolidine, purity profiles and polymorphs |
Apr, 2042
(17 years from now) | |
Defencath is owned by Cormedix.
Defencath contains Heparin Sodium; Taurolidine.
Defencath has a total of 4 drug patents out of which 0 drug patents have expired.
Defencath was authorised for market use on 15 November, 2023.
Defencath is available in solution;n/a dosage forms.
Defencath can be used as a catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter.
Drug patent challenges can be filed against Defencath from 15 November, 2032.
The generics of Defencath are possible to be released after 15 April, 2042.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Generating Antibiotic Incentives Now(GAIN) | Nov 15, 2033 |
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
Drugs and Companies using HEPARIN SODIUM; TAUROLIDINE ingredient
NCE-1 date: 15 November, 2032
Market Authorisation Date: 15 November, 2023
Treatment: A catheter lock solution to reduce catheter-related bloodstream infections in adult patients receiving hemodialysis through a central venous catheter
Dosage: SOLUTION;N/A
DEFENCATH family patents
